Capecitabine and Pegylated Interferon Alfa-2a in Treating Patients With Recurrent or Progressive Brain Metastases Due to Breast Cancer
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Metastatic Cancer
Interventions: BIOLOGICAL: PEG-interferon alfa-2a|DRUG: Capecitabine
Sponsor: M.D. Anderson Cancer Center
Collaborators: National Cancer Institute (NCI)